Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

ABSTRACT:

Background

Two nucleos(t)ide reverse transcriptase inhibitors (NRTIs)--abacavir and didanosine--may each be associated with excess risk of myocardial infarction. The reproducibility of this finding in an independent dataset was explored and plausible biological mechanisms were sought.

Methods

Biomarkers, ischemic changes on the electrocardiogram, and rates of various predefined types of cardiovascular disease (CVD) events according to NRTIs used were explored in the Strategies for Management of Anti-Retroviral Therapy (SMART) study. Patients receiving abacavir and not didanosine were compared with those receiving didanosine, and to those receiving NRTIs other than abacavir or didanosine (other NRTIs). Patients randomly assigned to the continuous antiretroviral therapy arm of

SUBMITTER: Strategies for Management of Anti-Retroviral Therapy/INSIGHT 

PROVIDER: S-EPMC2644883 | biostudies-literature | 2008 Sep

REPOSITORIES: biostudies-literature